CABLIVI (caplacizumab) is the first licensed disease-modifying treatment for aTTP1

The National Institute for Health and Care Excellence (NICE) has recommended the use of CABLIVI in line with its full indication.1

CABLIVI is indicated for the treatment of adults and adolescents of 12 years of age and older weighing at least 40 kg experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), in conjunction with plasma exchange (PEX) + immunosuppression (IMS).2

CABLIVI is the only adjunctive therapy for aTTP supported by randomised clinical trial data and real-world evidence.2–4



See how CABLIVI plus PEX+IMS can help you achieve platelet normalisation in your patients with aTTP faster, protect patients from aTTP-related death and reduce hospital resource use vs. PEX+IMS alone.2




View the most frequent adverse events, warnings and precautions associated with CABLIVI.




Consult the recommended dosing schedule for CABLIVI.



Mechanism of action

Discover CABLIVI’s innovative, disease-modifying mechanism of action (MOA).



CABLIVI: Maximise your efficacy in aTTP treatment.

CABLIVI has been assessed in two controlled Phase III clinical trials (Scully M, et al. 2019 and Coppo P, et al. 2021).3,4 Pooled analysis of the data from the Phase II TITAN5 and Phase III HERCULES3 trials was recently published by Peyvandi F, et al. 2021 in Blood Advances, confirming the findings from the other two studies in terms of mortality, refractory disease and safety data.6

CABLIVI plus PEX+IMS helps patients achieve a platelet response when they need it most.2–4


CABLIVI’s safety profile has been investigated in controlled clinical trials and is consistent with its mechanism of action in aTTP.2

  • Bleeding events associated with CABLIVI were generally self-limited, and all events in the Phase III clinical trial resolved, most without intervention2,3
  • CABLIVI plus PEX+IMS had a lower discontinuation rate (7% [5/71]) vs. PEX+IMS alone (12.3% [9/73])3

1 patient withdrew from the trial.3

Be ready for aTTP.

CABLIVI dosing schedule.

CABLIVI is administered by both intravenous (IV) and subcutaneous (SC) injection and should be initiated and supervised by physicians experienced in the management of patients with thrombotic microangiopathies.2


prominent presenting features

BSH webinar: Improvements in follow-up

For notifications about events and meetings, new information, publications and resources, sign up here.

Further resources
Speed of Treatment

BSH webinar: speed of treatment initiation


CABLIVI information leaflet


To order patient materials, please visit Sanofi Medisa.

Diagnosing and referring quickly is key to reducing the high rate of mortality.6–8

CABLIVI: is an innovative therapy designed to act on the underlying disease pathology of aTTP.2

CABLIVI is a humanised nanobody that rapidly binds to the A1 domain of von Willebrand factor (vWF) preventing the ultra-large von Willebrand factor (ULvWF) mediated platelet adhesion characteristic of aTTP.2,9


CABLIVI plus PEX+IMS provides protection from microthrombi within 24 hours.2,9

Watch the animation below for a reminder of the pathophysiology of aTTP, or see About aTTP.

Educational animation: pathogenesis of aTTP

Find out more about how to initiate CABLIVI treatment through the specialised service.


ADAMTS13, a disintegrin and metalloprotease with thrombospondin type 1 motif, member 13; aTTP, acquired thrombotic thrombocytopenic purpura; BSH, British Society for Haematology; ICU, intensive care unit; IMS, immunosuppression; IV, intravenous; NICE, National Institute for Health and Care Excellence; PEX, plasma exchange; SC, subcutaneous; ULvWF, ultra-large von Willebrand factor; vWF, von Willebrand factor.



1. National Institute for Health and Care Excellence (NICE). Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura. TA667. December 2020. Available at: Accessed September 2021.
2. CABLIVI Summary of Product Characteristics.
3. Scully M, Cataland SR, Peyvandi F, et al. N Engl J Med. 2019;380(4):335–346.
4. Coppo P, Bubenheim M, Axoulay E, et al. Blood. 2021;137(6);733–742.
5. Peyvandi F, Scully M, Kremer Hovinga JA, et al. N Engl J Med. 2016;374(4):335–346.
6. Peyvandi F, Cataland S, Scully M, et al. Blood Adv. 2021;5(8):2137–2141.
7. Scully M, Hunt BJ, Benjamin S, et al. Br J Haematol. 2012;158(3):323–335.
8. Scully M, Yarranton H, Liesner R, et al. Br J Haematol. 2008;142(5):819–826.
9. Peyvandi F, Scully M, Kremer Hovinga J, et al. N Engl J Med. 2016;374(6):511–522.

This website uses cookies to track its audience and improve its content. By continuing to browse this website, you agree to the use of such cookies.
Cookie Policy
Accept Cookies